JLL Capital Markets secured $182M in construction financing & equity for Latigo Group's 333-unit Hillcrest Apartments in ...

Artificial intelligence chatbots are fast becoming staples of modern office life, but it’s clear that not all tools are ...

Despite investing tens of billions of dollars into OpenAI, Microsoft is still, apparently, competing with its business ...

Viking Therapeutics VKTX announced that it has initiated the phase III VANQUISH program, evaluating the subcutaneous (SC) ...

For high-risk patients with type 2 diabetes, oral semaglutide reduced risk for major cardiovascular and ischemic limb-related ...

AI partners Microsoft and OpenAI’s cooling relationship cools further with Amgen’s switch from Copilot to ChatGPT.

Talented female scientists are being pushed out of cancer research due to gender discrimination, ageism and an absence of ...

Drugs such as Ozempic (a brand name for semaglutide) are showing promise for weight loss. Another medication in the same ...

A new drug, 'MariTide,' developed by Amgen, has shown significant potential in treating obesity, with trial participants losing up to 16% body weight annually.

Amgen’s first quarter results reflected robust demand across its portfolio, with product volumes and sales increasing in both ...

Oppenheimer & Co. Inc. trimmed its stake in Amgen Inc. by 1.2% in Q1, selling 1,335 shares, bringing its holding to 109,833 ...

In the most recent trading session, Amgen (AMGN) closed at $280.35, indicating a +1.03% shift from the previous trading day.